CoverageForm 410-K10-Q8-K13D13G13F

MNKD · Mannkind Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MNKD

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$348.97M$285.50M$198.96M$99.77M$75.44M$65.14M
Cost of Revenue$26.80M$17.43M$20.86M$16.00M$16.83M$15.08M
Gross Profit$322.17M$268.07M$178.10M$83.77M$58.61M$50.06M
R&D$66.35M$45.89M$31.28M$19.72M$12.31M$6.25M
SG&A$144.13M$94.33M$42.54M$24.68M$77.42M$59.04M
Total Operating Expenses$87.96M$76.60M$62.77M$24.64M$122.46M$113.06M
D&A$12.28M$7.37M$4.54M$6.12M$4.21M$2.15M
Operating Income$38.80M$72.59M$8.68M($64.11M)($47.02M)($47.91M)
Interest Expense$13.83M$11.98M$15.15M$1.37M$15.20M$4.32M
Income Tax($4.46M)$2.93M$1.56M$0$0($218.0K)
Net Income$5.86M$27.59M($11.94M)($87.40M)($80.93M)($57.24M)
EPS - Basic$0.02$0.10($0.04)($0.26)($0.32)-
EPS - Diluted$0.02$0.10($0.04)($0.26)($0.32)-

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents$74.88M$46.34M$238.48M$69.77M$124.18M$67.00M
Accounts Receivable$38.37M$11.80M$14.90M$16.80M$4.99M$4.22M
Inventory$35.31M$27.89M$28.55M$21.77M$7.15M$4.97M
Accounts Payable$9.03M$6.79M$9.58M$11.05M$6.96M$5.58M
Current Assets$291.58M$268.31M$373.39M$234.90M$219.74M$79.48M
Total Assets$792.18M$393.84M$475.20M$295.28M$321.16M$108.61M
Current Liabilities$171.03M$81.84M$104.13M$67.30M$48.35M$73.70M
Long-term Debt$354.64M$36.05M$268.70M$273.49M$281.20M$122.23M
Total Liabilities$843.20M$472.66M$721.37M$545.82M$530.51M$289.03M
Stockholders' Equity($51.02M)($78.82M)($246.17M)($250.54M)($209.35M)($180.42M)
Retained Earnings($3.20B)($3.20B)($3.23B)($3.22B)($3.13B)($3.05B)

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow$18.25M$42.51M$34.09M($80.68M)($61.71M)($28.13M)
Investing Cash Flow($304.80M)($96.65M)($1.99M)$4.87M($151.54M)$15.22M
Financing Cash Flow$315.10M($137.27M)$136.61M$21.39M$270.27M$49.85M
CapEx$4.57M$9.69M$42.44M$7.59M$11.47M$801.0K
Free Cash Flow$13.69M$32.82M($8.35M)($88.27M)($73.17M)($28.93M)

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin92.3%93.9%89.5%84.0%77.7%76.8%
Operating margin11.1%25.4%4.4%-64.3%-62.3%-73.5%
EBITDA margin14.6%28.0%6.6%-58.1%-56.7%-70.3%
Net margin1.7%9.7%-6.0%-87.6%-107.3%-87.9%
Free cash flow margin3.9%11.5%-4.2%-88.5%-97.0%-44.4%
FCF / Net income2.331.190.701.010.900.51
R&D / Revenue19.0%16.1%15.7%19.8%16.3%9.6%
SG&A / Revenue41.3%33.0%21.4%24.7%102.6%90.6%
Effective tax rate-316.7%9.6%----
Return on assets0.7%7.0%-2.5%-29.6%-25.2%-52.7%
Return on equity-11.5%-35.0%4.8%34.9%38.7%31.7%
Return on invested capital12.8%-30.4%-220.7%-51.7%-
Liquidity
Current ratio1.703.283.593.494.541.08
Quick ratio1.502.943.313.174.401.01
Cash ratio0.440.572.291.042.570.91
Leverage
Debt / Equity-6.95-0.46-1.09-1.09-1.34-0.68
Debt / Assets0.450.090.570.930.881.13
Debt / EBITDA6.940.4520.34---
Interest coverage2.8x6.1x0.6x-46.7x-3.1x-11.1x
Equity multiplier-15.53-5.00-1.93-1.18-1.53-0.60
Liabilities / Assets1.061.201.521.851.652.66
Efficiency
Asset turnover0.440.720.420.340.230.60
Inventory turnover0.760.630.730.742.353.03
Days sales outstanding40d15d27d61d24d24d
Days inventory outstanding481d584d499d497d155d120d
Days payable outstanding123d142d168d252d151d135d
Cash conversion cycle398d457d359d306d28d9d
Valuation
P / E283.5x64.3x----
P / B------
P / S5.1x6.4x4.9x11.8x14.4x-
EV / EBITDA40.3x22.7x75.8x---
Growth
Revenue growth (YoY)22.2%43.5%99.4%32.2%15.8%3.3%
Revenue CAGR (3y)51.8%55.8%45.1%16.5%-24.4%77.0%
Revenue CAGR (5y)39.9%35.3%2.6%53.4%-15.5%-
Gross profit growth (YoY)20.2%50.5%112.6%42.9%17.1%16.5%
Operating income growth (YoY)-46.5%736.4%--36.3%1.9%-7.4%
Net income growth (YoY)-78.7%-86.3%-8.0%-41.4%-10.3%
EPS growth (YoY)-80.0%-84.6%18.8%--
EPS CAGR (3y)------
EPS CAGR (5y)------
FCF growth (YoY)-58.3%-90.5%-20.6%-152.9%68.2%
FCF CAGR (5y)------
Book value growth (YoY)35.3%68.0%1.7%-19.7%-16.0%5.3%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$348.97M total
All Other Segments$348.97M · 100.0%

Product / service

$685.55M total
Product Revenue$216.52M · 31.6%
Royalty$128.12M · 18.7%
Product$114.14M · 16.6%
License And Service$106.71M · 15.6%
Afrezza$74.59M · 10.9%
Furoscix$23.18M · 3.4%
VGo$16.37M · 2.4%
Service$4.33M · 0.6%
Manufacturing Services$1.60M · 0.2%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-2.74
Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

3/9
Weak
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • Long-term debt decreased
  • Current ratio improved
  • No share dilution
  • Gross margin improved
  • Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing MANNKIND CORP against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.